Preadmission usage of metformin and mortality in COVID-19 patients including the post-discharge period
Author:
Publisher
Springer Science and Business Media LLC
Subject
General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s11845-021-02823-9.pdf
Reference31 articles.
1. Apicella M, Campopiano MC, Mantuano M et al (2020) COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol 8:782–792. https://doi.org/10.1016/S2213-8587(20)30238-2
2. Barron E, Bakhai C, Kar P et al (2020) Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol 8:813–822. https://doi.org/10.1016/S2213-8587(20)30272-2
3. Guo W, Li M, Dong Y et al (2020) Diabetes is a risk factor for the progression and prognosis of COVID -19. Diabetes Metab Res Rev 36:e3319. https://doi.org/10.1002/dmrr.3319
4. Kajiwara C, Kusaka Y, Kimura S et al (2018) Metformin mediates protection against Legionella pneumonia through activation of AMPK and mitochondrial reactive oxygen species. J Immunol 200:623–631. https://doi.org/10.4049/jimmunol.1700474
5. Chen Y, Gu F, Guan J-L (2018) Metformin might inhibit virus through increasing insulin sensitivity. Chin Med J (Engl) 131:376–377. https://doi.org/10.4103/0366-6999.223856
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Metformin as a Therapeutic Agent for Obesity-Associated Immune Dysfunction;The Journal of Nutrition;2024-08
2. Metformin is a potential therapeutic for COVID-19/LUAD by regulating glucose metabolism;Scientific Reports;2024-05-30
3. Metformin use associated with lower rate of hospitalization for influenza in individuals with diabetes;Diabetes, Obesity and Metabolism;2024-05-14
4. The Effect of Antihyperglycemic Medications on COVID-19: A Meta-analysis and Systematic Review from Observational Studies;Therapeutic Innovation & Regulatory Science;2024-04-29
5. Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic review and meta-analysis;Diabetologia;2023-05-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3